The Qiagen-founded precision cancer technology provider agreed to an acquisition by Invitae sized at at least $325m in cash and shares currently valued at about $820m.
Genetic information provider Invitae agreed yesterday to acquire US-based genetic testing technology developer ArcherDX in a deal valued at about $1.4bn that will allow medical researcher Qiagen to exit.
The transaction will consist of $325m in cash and 30 million shares of Invitae stock, which have subseuqently risen some 40% to $27.30 since Friday, in addition to 27 million more shares dependent on certain milestones being met.
ArcherDX has created a range of precision oncology products informed by genetic sequencing…
